Potent and Selective Oral IRF5 Degrader, KT-579, Demonstrates Robust Anti-Inflammatory Activity and Disease Modulation in Preclinical In Vivo Models of Inflammatory Bowel Disease

Potent and Selective Oral IRF5 Degrader, KT-579, Demonstrates Robust Anti-Inflammatory Activity and Disease Modulation in Preclinical In Vivo Models of Inflammatory Bowel Disease

Digestive Disease Week (DDW) 2026

Ryan Camire, Erik Corcoran, Emily Lurier, Jordan Leedberg, Virginia Massa, Yi Zhang, Chris Carroll, Chris Ho, Dapeng Chen, Matthew Lalonde, Revonda Mehovic, Rahul Karnik, Ziyan Zhao, Charles Howarth, Susanne Breitkopf, Sarah Martinez, Eric Kuhn, Sushrut Kamerkar, Murugappan Sathappa, Juliet Williams, Nello Mainolfi, Veronica Campbell